ReviewIBRO neuroscience reports2025
Role of isoflavones in multiple sclerosis.
Review in IBRO neuroscience reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myelin degeneration is a hallmark of multiple sclerosis, a chronic, autoimmune neurological condition that alters Central Nervous System communication. Despite the fact that the pathophysiology of multiple sclerosis is multifactorial and not fully understood, new research indicates that reducing oxidative stress and inflammation may have therapeutic advantages. A class of phytoestrogens called isoflavones, which are mostly present in soy and other legumes, have drawn interest because of their possible anti-inflammatory and neuroprotective properties. A comprehensive literature review was performed covering the period from 2000 to 2024, utilizing various databases such as PubMed, Scopus, ScienceDirect, and Google Scholar. This process involved the use of specific search terms and Boolean operators, including "isoflavones" AND "multiple sclerosis," "phytoestrogens" AND "neuroprotection," and "soy isoflavones" AND "autoimmune diseases," to locate relevant articles. The function of isoflavones in multiple sclerosis is examined in this review, with particular attention paid to their mechanisms of action, which include immune response modulation, antioxidant effects, and possible influence on neurodegenerative processes. This review discusses the preclinical data that currently supports isoflavones' capacity to lower inflammation, enhance myelin repair, and slow the progression in MS models. Future research directions are proposed, highlighting the challenges and limitations in implementing these findings in clinical practice. Even though isoflavones are still being studied, their promising role in MS treatment highlights the need for more research to assess their potential as supplemental therapies in managing MS symptoms and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.